Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02481050 |
| Title | Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer |
| Recruitment | Completed |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Eisai Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |